News >

Search Continues for Optimal HIPEC Use in Ovarian Cancer

Caroline Seymour
Published: Friday, May 24, 2019

Ernest S. Han, MD, PhD, FACOG

Ernest S. Han, MD, PhD, FACOG

Most high-volume centers are equipped to perform primary debulking in patients with advanced ovarian cancer, but for candidates who proceed with neoadjuvant chemotherapy instead, adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of interval debulking may improve survival, explained Ernest S. Han, MD, PhD, FACOG.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication